Large gap with delayed quotes
|
Last quote
02/07/2026
-
02:00:00
|
Bid
02/06/2026 -
21:59:59
|
Bid Volume |
Ask
02/06/2026 -
21:59:59
|
Ask Volume |
|---|---|---|---|---|
|
328.16
-3.08
(
-0.93% )
|
327.94
|
1,040 |
328.25
|
720 |
Analysis date: 03.02.2026
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 13.05.2025.
Interest
Very weak
Very weak
One star since 30.01.2026.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 30.01.2026 at a price of 338.06.
Evaluation
Undervalued
Undervalued
Based on its growth potential and our own criteria, we believe the share price is currently moderately undervalued.
MT Tech Trend
Negative
Negative
The dividend-adjusted forty day technical trend is negative since 09.12.2025.
4wk Rel Perf
-12.95%
-12.95%
The four-week dividend-adjusted underperformance versus SP500 is 12.95%.
Sensibility
Middle
Middle
The stock has been on the moderate-sensitivity level since 20.05.2025.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.64%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 2.84%.
Mkt Cap in $bn
44.80
44.80
With a market capitalization >$8bn, ALNYLAM PHARMACEUTICALS is considered a large-cap stock.
G/PE Ratio
2.30
2.30
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
25.22
25.22
The estimated PE is for the year 2028.
LT Growth
58.04%
58.04%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
18
18
Over the last seven weeks, an average of 18 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
65
65
For 1% of index variation, the stock varies on average by 0.65%.
Correlation
0.28
0.28
Stock movements are strongly independent of index variations.
Value at Risk
74.01
74.01
The value at risk is estimated at USD 74.01. The risk is therefore 21.04%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
13.12.2006
13.12.2006